Erbitux

Erbitux

cetuximab

Manufacturer:

PT. Merck Tbk
Concise Prescribing Info
Contents
Cetuximab
Indications/Uses
Patients w/ epidermal growth factor receptor (EGFR)-expressing KRAS wild-type metastatic colorectal cancer, in combination w/ chemotherapy or in patients who have failed oxaliplatin- & irinotecan-based therapy & who are intolerant to irinotecan. Patients w/ squamous cell cancer of the head & neck, in combination w/ radiation therapy for locally advanced disease or in combination w/ platinum-based chemotherapy for recurrent &/or metastatic disease.
Dosage/Direction for Use
Prior to infusion, patients must receive premed w/ an antihistamine & a corticosteroid. Initially 400 mg/m2 in 120-min IV infusion once wkly. Maintenance: 250 mg/m2 for 60 min once wkly. Max infusion rate: 10 mg/min.
Contraindications
Special Precautions
Monitor for infusion-related reactions. Discontinue if interstitial lung disease is diagnosed. Interrupt treatment in case of severe skin reaction (grade 3; NCI-CTC). Monitor serum electrolyte levels. Increased risk of severe neutropenia in combination treatment w/ platinum-based chemotherapy. Increased risk of CV events. Colorectal cancer patients w/ KRAS-mutated tumours. Pregnancy & lactation.
Adverse Reactions
Skin reactions, hypomagnesemia, infusion-related reactions, mucositis which may lead to epistaxis, increased liver enzyme levels.
Drug Interactions
Platinum-based chemotherapeutic agents, 5-fluorouracil infusion.
ATC Classification
L01XC06 - cetuximab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Erbitux inj 5 mg/mL
Packing/Price
(vial) 20 mL x 1's (Rp3,850,000/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in